These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 20868409)

  • 1. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
    Lynn R; Krunic A
    Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-grade prostate cancer and finasteride.
    Lebdai S; Bigot P; Azzouzi AR
    BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
    Sato A; Takeda A
    J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finasteride (Propecia) and the promotion of high-grade prostate cancer.
    Pitts WR
    Arch Dermatol; 2004 Jul; 140(7):885-6. PubMed ID: 15262708
    [No Abstract]   [Full Text] [Related]  

  • 5. Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern?
    Arias-Santiago S; Camacho-Martínez FM
    Actas Dermosifiliogr; 2016 Nov; 107(9):709-711. PubMed ID: 27436801
    [No Abstract]   [Full Text] [Related]  

  • 6. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB; Parekh DJ
    Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Finasteride adverse effects: An update].
    Carreño-Orellana N; Moll-Manzur C; Carrasco-Zuber JE; Álvarez-Véliz S; Berroeta-Mauriziano D; Porras-Kusmanic N
    Rev Med Chil; 2016 Dec; 144(12):1584-1590. PubMed ID: 28393993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
    Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
    J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up.
    Rossi A; Cantisani C; Scarnò M; Trucchia A; Fortuna MC; Calvieri S
    Dermatol Ther; 2011; 24(4):455-61. PubMed ID: 21910805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic hotline. Genetic variations in the androgen receptor gene and finasteride response in women with androgenetic alopecia mediated by epigenetics.
    Keene S; Goren A
    Dermatol Ther; 2011; 24(2):296-300. PubMed ID: 21410621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical applications of five-alpha reductase inhibitors.
    Loughlin KR
    Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finasteride-associated male infertility.
    Chiba K; Yamaguchi K; Li F; Ando M; Fujisawa M
    Fertil Steril; 2011 Apr; 95(5):1786.e9-11. PubMed ID: 21193189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer risk among users of finasteride and alpha-blockers - a population based case-control study.
    Murtola TJ; Tammela TL; Määttänen L; Hakama M; Auvinen A
    Eur J Cancer; 2007 Mar; 43(4):775-81. PubMed ID: 17251005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.
    Theoret MR; Ning YM; Zhang JJ; Justice R; Keegan P; Pazdur R
    N Engl J Med; 2011 Jul; 365(2):97-9. PubMed ID: 21675880
    [No Abstract]   [Full Text] [Related]  

  • 15. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.
    Goetzl MA; Holzbeierlein JM
    Nat Clin Pract Urol; 2006 Aug; 3(8):422-9. PubMed ID: 16902518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
    Mellon JK
    Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous finasteride therapy for benign prostate hypertrophy upgrades both neuroendorcine differentiation and aggressive prostate cancer.
    Tarle M; Spajic B; Kraljic I; Kusic Z
    Anticancer Res; 2009 May; 29(5):1797-801. PubMed ID: 19443407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finasteride: middle-age cure-all for alopecia and benign prostatic hyperplasia?
    Federman DG
    Mayo Clin Proc; 2006 Feb; 81(2):267; author reply 267-8. PubMed ID: 16471089
    [No Abstract]   [Full Text] [Related]  

  • 20. Guidelines on the use of finasteride in androgenetic alopecia.
    Mysore V; Shashikumar BM
    Indian J Dermatol Venereol Leprol; 2016; 82(2):128-34. PubMed ID: 26924401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.